Updated guidance from England's health technology assessment body, the National Institute for Health and Care Excellence (NICE), says that two neurostimulation technologies for treatment-resistant depression and epilepsy should only be used under special conditions, and that further evidence is needed to support their widespread use.
NICE said that evidence on the safety of implanted vagus nerve stimulation (VNS) for treatment-resistant depression raises no major safety...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?